SCHEMBL19968895

SCHEMBL19968895

CC1CCCN(c2cccc(S(=O)(=O)Nc3ccc(C(F)(F)F)c(-c4cc(Cl)ccc4OC(C)C)n3)n2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMOX1 P09601 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
SCN1A P35498 3/20 0.33
SCN8A Q9UQD0 3/20 0.33
DRD2 P14416 3/20 0.33
ADRA1D P25100 3/20 0.33
ADRA1A P35348 3/20 0.33
ADRA1B P35368 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GALR2 O43603 1/20 0.32
GALR1 P47211 1/20 0.32
IL1B P01584 1/20 0.32
SCN10A Q9Y5Y9 2/20 0.32
JAK2 O60674 2/20 0.32
JAK1 P23458 2/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19968902 0.92 GALR2 (0.38) ALDH1A1MAPTLMNAPOLBMAPK1
SCHEMBL19968894 0.92 GALR2 (0.38) ALDH1A1MAPTLMNAPOLBMAPK1
SCHEMBL19968890 0.91 HMOX1 (0.37) HMOX1ALDH1A1MAPTLMNAMAPK1
SCHEMBL19951421 0.84 DGAT1 (0.34) HMOX1SCN10AJAK2JAK1
SCHEMBL19968885 0.84 HSD11B1 (0.40) ALDH1A1MAPTLMNAPOLBMAPK1
SCHEMBL19951362 0.83 RORC (0.34) HMOX1POLBSCN1ASCN8AJAK2
SCHEMBL19968892 0.83 TP53 (0.38) MAPTSCN1ASCN8AKCNT1
SCHEMBL23770670 0.82 GALR2 (0.36) ALDH1A1MAPTLMNAPOLBMAPK1
SCHEMBL19968888 0.82 GALR2 (0.36) ALDH1A1MAPTLMNAPOLBMAPK1
SCHEMBL23651293 0.80 FFAR2 (0.38) SCN1ASCN8ASCN10AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 HMOX1 3249/4885ALDH1A1 1455/4885MAPT 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.